Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study is aimed to explore the antitumor activity and the safety profile of atezolizumab
in pretreated advanced NSCLC patients with rare histological subtypes.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Oncologico Italiano di Ricerca Clinica
Collaborators:
AOU S. Orsola Malpighi - Clinical Trial Office AOU S.Orsola Malpighi-Unit of Oncologic Molecular and Transplantations Pathology Iqvia Pty Ltd IQVIA Solutions Italy S.r.l. Istituto Toscano Tumori Roche SpA Silvano Chiapparoli Logistica SpA Yghea, CRO Division of Bioikos Ambiente srl YGHEA, CRO Division of Ecol Studio spa